Skip to main content
Equibles
ZTS logo

ZTS · Zoetis Inc.

Track ZTS — free

Use ZTS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZTS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$83.82 +0.86 (+1.04%) At close · Nov 13
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$34.06B
Shares
406.32M
Volume · Nov 13 3.15M Avg daily vol (3M) 4.53M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$83.82 Open$83.50 Day$82.27–83.85 52W close$69.10–131.10 Avg vol 30d4.4M Short int16.7M · 4.1% of shares · 4.8d Short vol57% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Next earnings call
Feb 11, 2027 Est · unconfirmed · in 13 wks
Q3 2026 earnings call transcript
call held Nov 5, 2026
Play latest call

Latest documents

2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue slips as U.S. weakness offsets international growth

Zoetis reported a 1% revenue decline and an 18% net income decline for the three months ended September 30, 2026. U.S. revenue fell 6%, while international revenue rose 4%.

Revenue $2.39B ▼ 1.3% Net income $591M ▼ 18.0% Diluted EPS $1.44 ▼ 11.7%
Read from the MD&A section
4 source passages
Total revenue decreased by $31 million, or 1%, for the three months ended September 30, 2026, compared with the three months ended September 30, 2025, a decrease of $44 million, or 2%, on an operational basis. U.S. segment revenue decreased by $76 million, or 6%, in the three months ended September 30, 2026, compared with the three months ended September 30, 2025, reflecting a decrease of $89 million in companion animal products, partially offset by an increase of $13 million in livestock products. International segment revenue increased by $42 million, or 4%, in the three months ended September 30, 2026 compared with the three months ended September 30, 2025. Operational revenue increased by $29 million, or 3%. Companion animal sales were flat in the current period while livestock products grew $29 million. Net income attributable to Zoetis | 591 | 721 | (18) | 3 | (21) Open the document at this passage
Nov 5
Earnings call
Revenue declines 1%; full-year guidance narrows

Zoetis reported third-quarter revenue of $2.4 billion, down 1%, and adjusted EPS of $1.75, up 1%. Full-year revenue guidance narrowed to $9.22 to $9.32 billion, while adjusted net income guidance rose to $2.6 to $2.64 billion and adjusted diluted EPS to $6.25 to $6.35.

6 source passages
Good morning, everyone, and welcome to the Zoetis 3rd Quarter 2026 Earnings Call. We delivered revenue of $2.4 billion, declining 1% on both a reported and organic operational basis, in line with our expectations, driven by a 1% price decline and flat volume. We delivered adjusted EPS of $1.75 in the quarter, up 1%, driven by the lower share count due to our ongoing share repurchase activity. We're narrowing our full-year revenue guidance to $9.22 to $9.32 billion, representing an organic operational decline of negative 2 to negative 1 percent year-over-year. We're raising our adjusted net income guidance to $2.6 to $2.64 billion, representing organic operational decline of negative 7% to negative 5%. We're also raising adjusted diluted EPS to $6.25 to $6.35. Open the document at this passage
Nov 5
Current report 8-K
Revenue Falls, Adjusted EPS Rises, Guidance Updated

Zoetis reported revenue of $2.4 billion, down 1%, and adjusted diluted EPS of $1.75, up 3%. It narrowed full year 2026 revenue guidance and raised adjusted diluted EPS guidance to $6.25 to $6.35.

Financial results
5 source passages
Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026. The company reported revenue of $2.4 billion for the third quarter of 2026, a decrease of 1% on a reported and an organic operational1 basis compared with the third quarter of 2025. Adjusted diluted EPS was $1.75, increasing 3% on a reported basis and 1% on an organic operational basis. Narrowed revenue to a range of $9.220 billion to $9.320 billion (organic operational growth of (2)% to (1)%) Raised adjusted diluted EPS to a range of $6.25 to $6.35 Open the document at this passage
Oct 8
Current report 8-K
Regulation FD disclosure

Zoetis Inc. declared a dividend of $0.53 per share for the fourth quarter of 2026, payable December 1, 2026, to shareholders of record at the close of business on October 30, 2026.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$9.49B
Trailing 12 months
Net income (TTM)
$2.51B
Trailing 12 months
Revenue growth YoY
-1.3%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
14.1
Trailing earnings · reciprocal yield 7.1%
FCF yield
6.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$7.52B
Latest balance sheet
Dividend yield
2.5%
Trailing 12 months
Shares change YoY
-7.1%
Year over year · fewer shares
Price change (1Y)
-30.8%
Trailing year
Short interest
4.1%
Latest settlement · 4.8 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲4.7% $2.32B $581.00M '24 Q4* ▲0.4% $2.20B $602.00M '25 Q1 ▲4.8% $2.47B $726.00M '25 Q2 ▲1.4% $2.42B $721.00M '25 Q3 ▲2.4% $2.37B $624.00M '25 Q4* ▲2.9% $2.26B $601.00M '26 Q1 ▼0.2% $2.47B $691.00M '26 Q2 LATEST ▼1.3% $2.39B $591.00M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26

TL;DR. Zoetis reported a Q2 miss with revenue and adjusted net income declining 1% and 2% organically amid U.S. companion animal weakness, and sharply cut full-year guidance to a (3)% to (1)% organic revenue decline and (9)% to (5)% adjusted net income decline, while livestock and diagnostics continued to grow strongly.

Bullish
  • + Livestock delivered 11% organic revenue growth in Q2 with U.S. livestock up 23%, supported by cattle and poultry
  • + International revenue grew 6% organically with emerging markets providing broad-based strength and Simparica Trio international up 34%
  • + Company repurchased over $550 million of shares in Q2, exceeding historical quarterly average, reflecting confidence and commitment to shareholder returns
  • + Adjusted SG&A declined 4% operationally reflecting cost and productivity discipline across the organization
  • + Lenivia and Portela long-acting OA pain therapies launched in EU and Canada with encouraging early experience
Bearish
  • − Full-year 2026 organic revenue guidance cut to (3)% to (1)% from prior 2% to 5%, and adjusted net income cut to (9)% to (5)% from prior 2% to 6%
  • − U.S. revenue declined 7% and U.S. companion animal declined 11% in Q2 on softer clinic visits and heightened competition
  • − U.S. Key Dermatology revenue declined 18% with in-clinic share down 10 points year-over-year amid new competitive entrants
  • − U.S. Simparica franchise declined 6% reflecting softer flea, tick, and heartworm visits and a more competitive and promotional environment
  • − Adjusted gross margin declined approximately 40 basis points reported and price expected to be flat to down 1-2% for the year as gross-to-net investments accelerate to defend share

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −8%
below
Price vs 50-day avg +10%
above
RSI (14) 59
neutral
MACD trend Negative
52-week position 24%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +6%
trailing
6-month return +4%
trailing
YTD return −33%
this year
Relative strength +4%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $76 › 200d $91 — 200d above 50d
Institutional flow Accumulating
1,326 of 1,451 funds reported for Sep 30 · net +6.6M sh shares · +101 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.12% of shares out · ▼ -4.6% MoM · 4.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1,451 holders — near 3-yr low, contrarian setup
Squeeze score 61
elevated · 0–100
Fundamentals
Strong
Revenue growth +2%
Y/Y
EPS growth +10%
Y/Y
Free cash flow $2.3B
Valuation P/E 14.1
below peers
Buyback $1.3B
remaining
Balance sheet $6.6B
net debt
Quant / Vol
risk profile
High
Volatility 38%
annualized · 1-yr
Max drawdown −47%
past year
ATR 3.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 8
Latest guidance · from the 8-K filed Aug 6, 2026
Full Year 2026
Revenue Lowered $9.12B – $9.32B
May 7, 2026 $9.68B – $9.96B changed to Aug 6, 2026 $9.12B – $9.32B
prior FY $9.47B midpoint −2.6% Y/Y
Adjusted net income Lowered $2.57B – $2.62B
May 7, 2026 $2.87B – $2.95B changed to Aug 6, 2026 $2.57B – $2.62B
Reported net income Lowered $2.33B – $2.38B
May 7, 2026 $2.68B – $2.76B changed to Aug 6, 2026 $2.33B – $2.38B
Full Year 2026 as of August 6, 2026
Organic operational results -3% – -1%
Previous outlook earlier release · from the 8-K filed May 7, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted cost of sales as a percentage of revenue · Full Year 2026 28.5%
Effective tax rate on adjusted income · Full Year 2026 20.5%
Prior guidance period ended · from the Earnings Call filed Dec 2, 2025
Full year revenue · full year $9.4B – $9.48B
Organic operational growth · full year 2025 5.5% – 6.5%
Adjusted net income organic operational growth · full year 2025 5.5% – 7%
Guided vs delivered · last 8 settled
Full year revenue full year
guided $9.4B – $9.48B
$9.47B In line
Reported diluted EPS full year 2025
guided $5.90 – $6.00
$6.02 Beat +1.2%
Revenue Full Year 2024
guided $9.1B – $9.25B
$9.26B Beat +0.9%
Reported diluted EPS Full Year 2024
guided $5.35 – $5.45
$5.47 Beat +1.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−8% Bearish
Price vs 50-day avg
+10% Bullish
RSI (14)
59 Neutral
MACD trend
Negative Bearish
52-week position
24% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $76 › 200d $91 — 200d above 50d
Institutional flow Accumulating
1,326 of 1,451 funds reported for Sep 30 · net +6.6M sh shares · +101 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.12% of shares out · ▼ -4.6% MoM · 4.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1,451 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $69 Now $84 · 24% Range high $131
vs 200-day avg -8% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Non-GAAP adjusted EPS—diluted non-GAAP $1.87 the three months ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
GAAP GAAP reported EPS attributable to Zoetis—diluted $1.65
+$0.06 Purchase accounting adjustments—net of tax
+$0 Acquisition and divestiture-related costs—net of tax
+$0.16 Certain significant items—net of tax
= Non-GAAP adjusted EPS—diluted $1.87

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ZTS
Zoetis Inc.
this stock
$34.06B -33.4% +2.3% 14.1 4.1%
TAK
Takeda Pharmaceutical Co Ltd
 $68.47B +37.5% — — 0.1%
GALDY
Galderma Group AG
 $53.23B +10.1% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $51.92B +42.6% +4.3% 101.1 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
 $40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
1,399
% held
101.6%
Reported
1,326 of 1,451
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
901
View
Short & Settlement
Short Interest Falling
Shares short
16.7M
Days to cover
4.8d
Change
-797.8K sh
View
Short Volume
Short vol %
57%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
572
Value
$43.3K
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
39.7%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Sep 18, 2026
View
Financials
Financials
Revenue (FY)
$9.5B
Net income (FY)
$2.7B
EPS diluted
$6.02
View
Buybacks
Authorized
$6.0B
Remaining
$1.3B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 5, 2026
This year
23

Zoetis reported revenue of $2.4 billion, down 1%, and adjusted diluted EPS of $1.75, up 3%. It narrowed full year 2026 revenue guidance and raised adjusted diluted EPS guidance to $6.25 to $6.35.

View
Proposed Sales
Value
$298.7K
Shares
2.3K
Filed
Feb 17, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 16, 2026
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Zoetis Receives USDA License for…
Published
Nov 11, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
ZTS +5.6% +5.6% +4.5% +5.1% -33.4%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +3.0% +6.8% +4.0% +5.3% -44.0%

Capital returns

Latest dividend
$0.53 / share · ex Oct 30, 2026
Raised 6%
Paid (TTM)
$2.12 / share · 4 payouts
Dividend yield (TTM, derived)
2.53%
Full dividend history
Buyback program · as of Jun 30, 2026
Authorized
$6.00B
Spent (derived)
$4.70B
Remaining
$1.30B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1555280 CUSIP 98978V103 13F (30d) 1132 filings 1027 filers Visit website Investor relations